
Belantamab mafodotin, an antibody-drug conjugate targeting BCMA, offers a novel therapeutic approach for relapsed/refractory multiple myeloma (RRMM). By integrating an afucosylated monoclonal antibody with the cytotoxic agent MMAF, it disrupts microtubule formation and signaling in malignant plasma cells. Clinical trials, including DREAMM studies, highlight its efficacy and potential in overcoming therapy resistance in RRMM. The review explores its mechanism, pre-clinical findings, and clinical impact, positioning it as a promising future treatment.
Like
Save
Share